Publications by authors named "Wayne Holman"

Claim this Profile
C
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.
Akshita Chawla, Ruthie Birger, Brian M Maas, Youfang Cao, Hong Wan, Wayne Holman

Clin Transl Sci· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
Sébastien Bihorel, Youfang Cao, Akshita Chawla, Ruthie Birger, Brian M Maas, Wayne Holman

CPT Pharmacometrics Syst Pharmacol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, Calley Middleton, Shazaad Ahmad, Wayne Holman

Lancet Infect Dis· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Richard FitzGerald, Laura Dickinson, Laura Else, Thomas Fletcher, Colin Hale, Wayne Holman

Clin Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
William A Fischer, Joseph J Eron, Wayne Holman, Myron S Cohen, Lei Fang

Sci Transl Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
Saye H Khoo, Richard Fitzgerald, Thomas Fletcher, Sean Ewings, Thomas Jaki, Wayne Holman

J Antimicrob Chemother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerated first-in-human clinical trial of EIDD-2801/MK-4482 (molnupiravir), a ribonucleoside analog with potent antiviral activity against SARS-CoV-2.
Wendy Holman, Wayne Holman, Stacy McIntosh, Wendy Painter, George Painter

Trials· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molnupiravir, an Oral Antiviral Treatment for COVID-19.
William Fischer, Joseph J Eron, Wayne Holman, Myron S Cohen, Lei Fang

medRxiv· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
Wendy P Painter, Wayne Holman, Jim A Bush, Firas Almazedi, Hamzah Malik

Antimicrob Agents Chemother· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis